LexisNexis has once again raised the bar for legal practitioners with a robust suite of new resources and tools in its Practical Guidance platform. The June 2025 updates span multiple practice areas, delivering...
Public Law No. 119-21, the One Big Beautiful Bill Act (OBBBA), represents the most comprehensive overhaul of the federal tax system since the Tax Cuts and Jobs Act of 2017 (TCJA). Enacted on July 4, 2025...
Restaurant leasing presents a unique blend of legal considerations, shaped by operational realities such as equipment needs, utility demands, and customer-facing enhancements. Review this checklist for...
In today’s deal-making space, environmental liabilities can be hidden landmines threatening post-closing value and operational integrity. Navigate the intricate terrain of M&A transactions where...
This practice note helps attorneys representing drug and medical device manufacturers advise their clients about liability risks associated with their products, by summarizing the legal landscape surrounding...
* The views expressed in externally authored materials linked or published on this site do not necessarily reflect the views of LexisNexis Legal & Professional.
The risk of drug trafficking activity is a top priority for U.S. regulatory agencies, as it generates the largest amount of illicit proceeds laundered in or through the U.S. financial system. The Treasury Department's Office of Foreign Assets Control (OFAC) is increasingly issuing sanctions to foreign organizations involved in smuggling illicit drugs into the United States. Watch this video, presented by Michael Robotti, a partner at Ballard Spahr LLP, for an overview of FinCEN's guidance to address anti-money laundering (AML) risks associated with Drug Trafficking Organization Activity.
Watch now »
Related Content
Practical Guidance Updates Featuring the latest updates from your Practical Guidance account.
Experience results today with practical guidance, legal research, and data-driven insights—all in one place.Experience Lexis+